Relapsed/Refractory Multiple Myeloma Clinical Trials

136 clinical trials for Relapsed/Refractory Multiple Myeloma across international registries, including 38 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) — RECRUITING · PHASE1
• A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — RECRUITING · PHASE1
• A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) — RECRUITING · PHASE3
• A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials — RECRUITING
• Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) — RECRUITING · PHASE4
• To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients — RECRUITING · PHASE3
• A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma — RECRUITING
• AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) — RECRUITING · PHASE1
• Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease — RECRUITING · PHASE1
• A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" — RECRUITING · PHASE2
• Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma — RECRUITING · PHASE1
• IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia — RECRUITING · PHASE2
• Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) — RECRUITING · PHASE1
• A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma — RECRUITING
• ELISA in Relapsed/Refractory MM — RECRUITING · PHASE2
• Long-Term Follow-up Study — RECRUITING
• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE3
• Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma — RECRUITING · NA
• A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma — RECRUITING · PHASE1
• Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy — RECRUITING · PHASE2
• Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia — RECRUITING · PHASE1
• CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — RECRUITING · PHASE1
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — RECRUITING · PHASE1
• A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma — RECRUITING · PHASE1
• An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors — RECRUITING · NA
• a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia — RECRUITING · PHASE1
• Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM — RECRUITING · NA
• UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma — RECRUITING · NA
• A clinical study of Ibrutinib taken together with Pomalidomide and Dexamethasone in patients with Multiple Myeloma (who have stopped responding or have failed to respond to current treatments) — COMPLETED · PHASE2
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma — TERMINATED · PHASE2
• A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma — TERMINATED · PHASE1
• BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma — TERMINATED · PHASE1
• A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. — NOT_YET_RECRUITING · PHASE2
• Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) — NOT_YET_RECRUITING · PHASE1
• Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy with Reduced versus Standard Dose of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (REBEL) — NOT_YET_RECRUITING · PHASE2
• Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens — COMPLETED
• A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search